Azithromycin maintains airway epithelial integrity during Pseudomonas aeruginosa infection.

Tight junctions (TJs) play a key role in maintaining bronchial epithelial integrity, including apical-basolateral polarity and paracellular trafficking. Patients with chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) often suffer from chronic infections by the opportunistic Gram-negative bacterium Pseudomonas aeruginosa, which produces multiple virulence factors, including rhamnolipids. The macrolide antibiotic azithromycin (azm) has been shown to improve lung function in patients with CF without reducing the bacterial count within the lung. However, the mechanism of this effect is still debated. It has previously been shown that azm increased transepithelial electrical resistance (TER) in a bronchial epithelial cell line. In this study we used an air-liquid interface model of human airway epithelia and measured TER, changes in TJ expression and architecture after exposure to live P. aeruginosa PAO1, and PAO1-Deltarhl which is a PAO1 mutant lacking rhlA and rhlB, which encode key enzymes for rhamnolipid production. In addition, the cells were challenged with bacterial culture medium conditioned by these strains, purified rhamnolipids, or synthetic 3O-C(12)-HSL. Virulence factors secreted by P. aeruginosa reduced TER and caused TJ rearrangement in the bronchial epithelium, exposing the epithelium to further bacterial infiltration. Pretreatment of the bronchial epithelium with azm attenuated this effect and facilitated epithelial recovery. These data suggest that azm protects the bronchial epithelium during P. aeruginosa infection independent of antimicrobial activity, and could explain in part the beneficial results seen in clinical trials of patients with CF.

[1]  B. Rubin,et al.  Macrolides as immunomodulatory medications for the therapy of chronic lung diseases. , 2008, Current opinion in pharmacology.

[2]  T. Murphy,et al.  Pseudomonas aeruginosa in chronic obstructive pulmonary disease. , 2008, American journal of respiratory and critical care medicine.

[3]  G. James,et al.  Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. , 2008, The Journal of antimicrobial chemotherapy.

[4]  K. Yagi,et al.  Targeting tight junction proteins-significance for drug development. , 2008, Drug discovery today.

[5]  A. Prince,et al.  The Type III Toxins of Pseudomonas aeruginosa Disrupt Epithelial Barrier Function , 2007, Journal of bacteriology.

[6]  M. Steinarsdóttir,et al.  Differentiation potential of a basal epithelial cell line established from human bronchial explant , 2007, In Vitro Cellular & Developmental Biology - Animal.

[7]  M. Conese,et al.  Pseudomonas aeruginosa infection destroys the barrier function of lung epithelium and enhances polyplex-mediated transfection. , 2007, Human gene therapy.

[8]  M. Hentzer,et al.  Azithromycin Blocks Quorum Sensing and Alginate Polymer Formation and Increases the Sensitivity to Serum and Stationary-Growth-Phase Killing of Pseudomonas aeruginosa and Attenuates Chronic P. aeruginosa Lung Infection in Cftr−/− Mice , 2007, Antimicrobial Agents and Chemotherapy.

[9]  I. Larre,et al.  New diseases derived or associated with the tight junction. , 2007, Archives of medical research.

[10]  C. F. van der Walle,et al.  Tight junction modulation and biochemical characterisation of the zonula occludens toxin C‐and N‐termini , 2007, FEBS letters.

[11]  A. Prince,et al.  Opportunistic infections in lung disease: Pseudomonas infections in cystic fibrosis. , 2007, Current opinion in pharmacology.

[12]  D. Look,et al.  Paracellular Permeability Restricts Airway Epithelial Responses to Selectively Allow Activation by Mediators at the Basolateral Surface1 , 2007, The Journal of Immunology.

[13]  B. Assael,et al.  Azithromycin Selectively Reduces Tumor Necrosis Factor Alpha Levels in Cystic Fibrosis Airway Epithelial Cells , 2007, Antimicrobial Agents and Chemotherapy.

[14]  K. Magnusson,et al.  Pseudomonas aeruginosa quorum sensing molecule N‐(3 oxododecanoyl)‐l‐homoserine lactone disrupts epithelial barrier integrity of Caco‐2 cells , 2006, FEBS letters.

[15]  B. Assael,et al.  Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells. , 2006, Biochemical and biophysical research communications.

[16]  B. Margolis,et al.  Tight junctions and cell polarity. , 2006, Annual review of cell and developmental biology.

[17]  D. Landau.  Epithelial paracellular proteins in health and disease , 2006, Current opinion in nephrology and hypertension.

[18]  J. Jais,et al.  Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial , 2006, Thorax.

[19]  P. Meda,et al.  Rhamnolipids Are Virulence Factors That Promote Early Infiltration of Primary Human Airway Epithelia by Pseudomonas aeruginosa , 2006, Infection and Immunity.

[20]  T. Gudjonsson,et al.  Novel Effects of Azithromycin on Tight Junction Proteins in Human Airway Epithelia , 2006, Antimicrobial Agents and Chemotherapy.

[21]  C. V. Van Itallie,et al.  Claudins and epithelial paracellular transport. , 2006, Annual review of physiology.

[22]  F. Lépine,et al.  Production of rhamnolipids by Pseudomonas aeruginosa , 2005, Applied Microbiology and Biotechnology.

[23]  B. Iglewski,et al.  Azithromycin Retards Pseudomonas aeruginosa Biofilm Formation , 2004, Journal of Clinical Microbiology.

[24]  M. Schultz.  Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis. , 2004, The Journal of antimicrobial chemotherapy.

[25]  M. King,et al.  Long term azithromycin therapy in cystic fibrosis patients: a study on drug levels and sputum properties. , 2004, Canadian respiratory journal.

[26]  R. Bals,et al.  Innate immunity in the lung: how epithelial cells fight against respiratory pathogens , 2004, European Respiratory Journal.

[27]  S. Brody,et al.  Foxj1 is required for apical localization of ezrin in airway epithelial cells , 2003, Journal of Cell Science.

[28]  L. Saiman,et al.  Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. , 2003, JAMA.

[29]  M. Welsh,et al.  Segregation of receptor and ligand regulates activation of epithelial growth factor receptor , 2003, Nature.

[30]  Roger S Smith,et al.  P. aeruginosa quorum-sensing systems and virulence. , 2003, Current opinion in microbiology.

[31]  A. Kirkham,et al.  Pseudomonas aeruginosa Quorum-Sensing Systems May Control Virulence Factor Expression in the Lungs of Patients with Cystic Fibrosis , 2002, Infection and Immunity.

[32]  J. Whitsett.  Series Introduction: Intrinsic and innate defenses in the lung: intersection of pathways regulating lung morphogenesis, host defense, and repair , 2002 .

[33]  K. Tateda,et al.  Azithromycin Inhibits Quorum Sensing in Pseudomonas aeruginosa , 2001, Antimicrobial Agents and Chemotherapy.

[34]  S. Kjelleberg,et al.  A novel and sensitive method for the quantification of N-3-oxoacyl homoserine lactones using gas chromatography-mass spectrometry: application to a model bacterial biofilm. , 2000, Environmental microbiology.

[35]  M. Plotkowski,et al.  Pseudomonas aeruginosa internalization by human epithelial respiratory cells depends on cell differentiation, polarity, and junctional complex integrity. , 1999, American journal of respiratory cell and molecular biology.

[36]  S. Fleiszig,et al.  Epithelial cell polarity affects susceptibility to Pseudomonas aeruginosa invasion and cytotoxicity , 1997, Infection and immunity.

[37]  B. Gumbiner,et al.  A Synthetic Peptide Corresponding to the Extracellular Domain of Occludin Perturbs the Tight Junction Permeability Barrier , 1997, The Journal of cell biology.

[38]  A. Pavirani,et al.  Differential localization of the cystic fibrosis transmembrane conductance regulator in normal and cystic fibrosis airway epithelium. , 1992, American journal of respiratory cell and molecular biology.

[39]  G. Taylor,et al.  Effect of Pseudomonas aeruginosa rhamnolipids on mucociliary transport and ciliary beating. , 1992, Journal of applied physiology.

[40]  B. Tümmler,et al.  RHAMNOLIPID OF PSEUDOMONAS AERUGINOSA IN SPUTUM OF CYSTIC FIBROSIS PATIENTS , 1987, The Lancet.

[41]  E. Giamarellos‐Bourboulis.  Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. , 2008, International journal of antimicrobial agents.

[42]  C. V. Van Itallie,et al.  The role of claudins in determining paracellular charge selectivity. , 2004, Proceedings of the American Thoracic Society.